Onyx hits biotech jackpot

Shares of Onyx Pharmaceuticals doubled today after Onyx and partner Bayer AG reported increased survival rates in a drug trial on patients with liver cancer. This drug, Nexavar, is currently approved for kidney cancer in 50 countries, but liver cancer poses a more serious problem, for which currently there is no treatment in the U.S.
Would this be it?

Watch Onyx CEO, Hollings Renton, interview with CNBC.